• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

华盛顿州枢纽辐射模式改善阿片类药物使用障碍治疗效果的有效性。

Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.

作者信息

Reif Sharon, Stewart Maureen T, Daily Shay M, Panas Lee, Ritter Grant A, Brolin Mary F, Lee Margaret T, Wicks Jennifer J

机构信息

Institute for Behavioral Health, Schneider Institutes for Health Policy and Research, Heller School for Social Policy and Management, Brandeis University, 415 South Street, Waltham, MA 02453, United States.

Department of Health Law, Policy and Management, Boston University School of Public Health, 715 Albany Street, Boston, MA 02118, United States.

出版信息

Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.

DOI:10.1093/haschl/qxaf157
PMID:40896384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12392894/
Abstract

INTRODUCTION

Innovative strategies remain necessary to increase utilization of medications for opioid use disorder (MOUD), an effective approach to reduce overdoses and deaths. The hub and spoke (HS) model is increasingly used to improve MOUD treatment, yet the impact is relatively unknown. We assessed the effectiveness of Washington State's hub and spoke (WA-HS) model on 6-month outcomes of MOUD continuity and health care utilization.

METHODS

We analyzed 25 368 adult Medicaid beneficiaries with new MOUD episodes in 2016-2019, comparing HS and non-HS cohorts in the 6 months after starting MOUD.

RESULTS

Across both cohorts, 26% stayed on MOUD for 6 months, and within 6 months of MOUD initiation, 42% had an emergency department (ED) visit, 14% had any hospitalization, and 13% entered intensive substance use treatment. No significant differences were found between cohorts for all outcomes.

CONCLUSION

Our null findings likely reflect the complexity of the OUD crisis, the many needs of people with OUD that require flexible approaches at the individual and systems levels, and the WA-HS focus on MOUD initiation. Findings highlight the need to ensure HS models incorporate strategies to address MOUD continuity to drive long-term recovery for people with OUD.

摘要

引言

创新策略对于提高阿片类物质使用障碍药物(MOUD)的利用率仍然至关重要,这是一种减少过量用药和死亡的有效方法。中心辐射(HS)模式越来越多地被用于改善MOUD治疗,但其影响相对未知。我们评估了华盛顿州中心辐射(WA-HS)模式对MOUD连续性和医疗保健利用率6个月结果的有效性。

方法

我们分析了2016年至2019年25368名有新MOUD发作的成年医疗补助受益人的情况,比较了开始MOUD治疗后6个月内HS队列和非HS队列。

结果

在两个队列中,26%的人持续使用MOUD达6个月,在开始使用MOUD的6个月内,42%的人去过急诊科,14%的人有过住院治疗,13%的人进入强化物质使用治疗。在所有结果方面,队列之间未发现显著差异。

结论

我们的阴性结果可能反映了阿片类物质使用障碍危机的复杂性、阿片类物质使用障碍患者的多种需求,这些需求需要在个人和系统层面采取灵活的方法,以及WA-HS模式对MOUD启动的关注。研究结果强调需要确保HS模式纳入解决MOUD连续性的策略,以推动阿片类物质使用障碍患者的长期康复。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3de9/12392894/1032d91be8b5/qxaf157f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3de9/12392894/1032d91be8b5/qxaf157f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3de9/12392894/1032d91be8b5/qxaf157f1.jpg

相似文献

1
Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.华盛顿州枢纽辐射模式改善阿片类药物使用障碍治疗效果的有效性。
Health Aff Sch. 2025 Aug 7;3(8):qxaf157. doi: 10.1093/haschl/qxaf157. eCollection 2025 Aug.
2
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.华盛顿州首个枢纽与辐条式队列研究中枢纽及治疗特征与客户结局的关系。
J Subst Use Addict Treat. 2025 Jan;168:209544. doi: 10.1016/j.josat.2024.209544. Epub 2024 Oct 20.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder.提升治疗参与度的示范医院启动试验(EXHIT ENTRE):CTN-0098方案,一项关于缓释丁丙诺啡与常规治疗对阿片类药物使用障碍住院患者出院后治疗参与度的开放标签随机对照有效性试验。
Addict Sci Clin Pract. 2024 Dec 2;19(1):91. doi: 10.1186/s13722-024-00510-5.
5
Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings.农村地区过渡年龄青年与26岁及以上成年人相比的阿片类物质使用障碍药物治疗情况
JAACAP Open. 2024 Feb 28;2(4):231-238. doi: 10.1016/j.jaacop.2024.02.001. eCollection 2024 Dec.
6
Differential Changes in Use of Medications for Opioid Use Disorder by Race-Ethnicity: Effects of a Hub-and-Spoke Model.按种族划分的阿片类物质使用障碍药物使用差异变化:中心-辐条模式的影响
Psychiatr Serv. 2025 Sep 1;76(9):795-800. doi: 10.1176/appi.ps.20240373. Epub 2025 Jun 25.
7
The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.阿片类药物使用障碍治疗研究:18 个月阿片类药物使用障碍治疗患者的研究方法和初步结果。
Public Health Rep. 2024 Jul-Aug;139(4):484-493. doi: 10.1177/00333549231222479. Epub 2024 Jan 25.
8
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.冰毒/苯丙胺使用对阿片类药物使用障碍药物治疗的获得和结果的影响:系统评价。
Addict Sci Clin Pract. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2.
9
Hospital readmissions and emergency department encounters among patients who initiate medications for opioid use disorder during hospitalization: Comparison of patients with and without co-occurring methamphetamine use.住院期间开始使用阿片类物质使用障碍药物治疗的患者的医院再入院情况及急诊科就诊情况:同时使用甲基苯丙胺与未同时使用甲基苯丙胺患者的比较。
J Subst Use Addict Treat. 2025 Oct;177:209765. doi: 10.1016/j.josat.2025.209765. Epub 2025 Jul 30.
10
Medication for opioid use disorder in the Arab World: A systematic review.阿拉伯世界阿片类药物使用障碍的药物治疗:系统评价。
Int J Drug Policy. 2022 Apr;102:103617. doi: 10.1016/j.drugpo.2022.103617. Epub 2022 Feb 16.

本文引用的文献

1
Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study.佛蒙特州农村地区以患者为中心的阿片类药物使用障碍药物治疗:一项定性研究
Addict Sci Clin Pract. 2025 Jan 14;20(1):3. doi: 10.1186/s13722-024-00529-8.
2
Examining the Impact of Eliminating the X Waiver on Buprenorphine Dispensation in 63 Counties in Pennsylvania.考察取消X豁免对宾夕法尼亚州63个县丁丙诺啡配药的影响。
Subst Use Addctn J. 2025 Jul;46(3):503-509. doi: 10.1177/29767342241303583. Epub 2024 Dec 15.
3
Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.
提高丁丙诺啡/纳洛酮治疗阿片类药物使用障碍的保留率的策略:来自处方者的问题和建议的定性研究。
Addict Sci Clin Pract. 2024 Nov 21;19(1):85. doi: 10.1186/s13722-024-00516-z.
4
Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.华盛顿州首个枢纽与辐条式队列研究中枢纽及治疗特征与客户结局的关系。
J Subst Use Addict Treat. 2025 Jan;168:209544. doi: 10.1016/j.josat.2024.209544. Epub 2024 Oct 20.
5
Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.美沙酮类物质使用障碍照护递进式治疗下丁丙诺啡的治疗和临床结局。
Drug Alcohol Depend. 2024 Oct 1;263:112389. doi: 10.1016/j.drugalcdep.2024.112389. Epub 2024 Aug 13.
6
Buprenorphine Prescribing Characteristics Following Relaxation of X-Waiver Training Requirements.放松 X 豁免培训要求后丁丙诺啡的处方特征。
JAMA Netw Open. 2024 Aug 1;7(8):e2425999. doi: 10.1001/jamanetworkopen.2024.25999.
7
The role of recovery peer navigators in retention in outpatient buprenorphine treatment: a retrospective cohort study.康复同伴导航员在门诊丁丙诺啡维持治疗中保持治疗的作用:一项回顾性队列研究。
Ann Med. 2024 Dec;56(1):2355566. doi: 10.1080/07853890.2024.2355566. Epub 2024 Jun 1.
8
Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.扩大阿片类药物使用障碍药物治疗的机会:华盛顿州中心辐射努力的结果。
Drug Alcohol Depend. 2024 Mar 1;256:111125. doi: 10.1016/j.drugalcdep.2024.111125. Epub 2024 Feb 14.
9
Pregnancy- and parenting-related barriers to receiving medication for opioid use disorder: A multi-paneled qualitative study of women in treatment, women who terminated treatment, and the professionals who serve them.妊娠和育儿相关因素对接受阿片类药物使用障碍药物治疗的阻碍:一项对治疗中的女性、终止治疗的女性以及为其提供服务的专业人员进行的多层面定性研究。
Womens Health (Lond). 2024 Jan-Dec;20:17455057231224181. doi: 10.1177/17455057231224181.
10
Barriers to retention in medications for opioid use disorder treatment in real-world practice.真实世界实践中阿片类药物使用障碍治疗药物维持治疗的障碍。
J Subst Use Addict Treat. 2024 May;160:209310. doi: 10.1016/j.josat.2024.209310. Epub 2024 Feb 7.